University of California San Francisco

Mattis 144.jpg
Aras N. Mattis, MD, PhD

Assistant Professor, UCSF Department of Pathology

Address

513 Parnassus Avenue, HSW, #516
San Francisco, CA 94143
United States

Email: [email protected]
Phone: 415-514-3062

    Biography

    Aras N. Mattis, M.D., Ph.D., is a board-certified anatomic pathologist and clinical fellow in the Willenbring Lab. Dr. Mattis trained at the University of Illinois at Urbana-Champaign, earning both his doctorates, Biochemistry and Medicine, there in 2007. He continued his clinical training in Pathology at the University of California San Francisco completing residency in Anatomic Pathology with subsequent fellowship training in Surgical Pathology and Liver and gastrointestinal pathology under his clinical mentor, Dr. Linda Ferrell. Since 2010, he has worked in the Willenbring Lab, investigating the basic mechanisms of liver development and disease in the with a specific focus on liver metabolism and fatty liver disease as well as micro-RNA regulation of liver metabolism.

    Education

    Institution Degree Dept or School End Date
    University of Illinois Urbana-Champaign PhD Biochemistry 2007
    University of Illinois Urbana-Champaign MD Medicine 2007
    University of California Berkeley BA Molecular and Cell Biology - Genetics 1998

    Board Certifications

    American Board of Pathology, Anatomic Pathology

    Collaboration Interests

    I am interested in:

    • academic collaboration
    • academic senate committee service
    • companies and entrepreneurs
    • multicenter clinical research
    • press
    • prospective donors

    Clinical Expertise

    Liver and Gastrointestinal Pathology

    Program Affiliations

    UCSF Department of Pathology

    California Institute for Regenerative Medicine

    Grants and Funding

    • Establishing patient-derived iPSCs as a platform for discovery research in NAFLD | NIDDK | 2023-06-01 - 2028-05-30 | Role: MPI
    • Modeling and Characterization of NAFLD Phenotypes in a Severely Affected Family | NIH/NIDDK | 2024-02-01 - 2027-11-30 | Role: PI
    • Genetic Regulation of Nonalcoholic Fatty Liver Disease | NIH | 2021-06-08 - 2025-03-31 | Role: MPI
    • Regulation of Lipid Metabolism by miR-29a within Hepatocytes | NIH | 2013-09-01 - 2019-07-31 | Role: Principal Investigator

    Research Narrative

    Dr. Mattis' postdoctoral work includes the use of translational human biopsy material as well as patient-derived induced pluripotent stem cell reprogramming to hepatocytes. As a long-term goal, this work aims to develop a humanized liver mouse model of fatty liver disease. Aras is supported by the UCSF CIRM clinical fellow training grant and continues to work closely with the UCSF Department of Pathology as a clinical researcher.

    Research Interests

    Liver diseases including metabolic, pediatric, fibrotic, idiopathic, stem cell derived

    Hepatocytes for transplant and disease modeling, micro-RNA regulation of hepatocyte

    Development and metabolism, liver and gastrointestinal tumors, site-specific recombination.

    Publications

    MOST RECENT PUBLICATIONS FROM A TOTAL OF 56
    1. Doxycycline Significantly Enhances Induction of Induced Pluripotent Stem Cells to Endoderm by Enhancing Survival Through Protein Kinase B Phosphorylation.
      Peaslee C, Esteva-Font C, Su T, Munoz-Howell A, Duwaerts CC, Liu Z, Rao S, Liu K, Medina M, Sneddon JB, Maher JJ, Mattis AN| | PubMed
    2. Gastric Intestinal Metaplasia in Mucosa Adjacent to Gastric Cancers Is Rarely Associated With the Aneuploidy That Is Characteristic of Gastric Dysplasia or Cancer.
      Zhang R, Rabinovitch PS, Mattis AN, Lauwers GY, Choi WT| | PubMed
    3. Persistent or recurrent Barrett's neoplasia after an endoscopic therapy session is associated with DNA content abnormality and can be detected by DNA flow cytometric analysis of paraffin-embedded tissue.
      Bowman CJ, Zhang R, Balitzer D, Wang D, Rabinovitch PS, Kovári BP, Mattis AN, Kakar S, Lauwers GY, Choi WT| | PubMed
    4. Induced Pluripotent Stem Cell-derived Hepatocytes From Patients With Nonalcoholic Fatty Liver Disease Display a Disease-specific Gene Expression Profile.
      Duwaerts CC, Le Guillou D, Her CL, Phillips NJ, Willenbring H, Mattis AN, Maher JJ| | PubMed
    5. Non-conventional dysplasia in inflammatory bowel disease is more frequently associated with advanced neoplasia and aneuploidy than conventional dysplasia.
      Lee H, Rabinovitch PS, Mattis AN, Lauwers GY, Choi WT| | PubMed
    6. Hepatocyte-specific deletion of XBP1 sensitizes mice to liver injury through hyperactivation of IRE1α.
      Duwaerts CC, Siao K, Soon RK, Her C, Iwawaki T, Kohno K, Mattis AN, Maher JJ| | PubMed
    7. Targeting acid ceramidase inhibits YAP/TAZ signaling to reduce fibrosis in mice.
      Alsamman S, Christenson SA, Yu A, Ayad NME, Mooring MS, Segal JM, Hu JK, Schaub JR, Ho SS, Rao V, Marlow MM, Turner SM, Sedki M, Pantano L, Ghoshal S, Ferreira DDS, Ma HY, Duwaerts CC, Espanol-Suner R, Wei L, Newcomb B, Mileva I, Canals D, Hannun YA, Chung RT, Mattis AN, Fuchs BC, Tager AM, Yimlamai D, Weaver VM, Mullen AC, Sheppard D, Chen JY| | PubMed
    8. Ly6cLo non-classical monocytes promote resolution of rhesus rotavirus-mediated perinatal hepatic inflammation.
      Alkhani A, Levy CS, Tsui M, Rosenberg KA, Polovina K, Mattis AN, Mack M, Van Dyken S, Wang BM, Maher JJ, Nijagal A| | PubMed
    9. Utility of DNA flow cytometry in distinguishing between malignant and benign intrahepatic biliary lesions.
      Wen KW, Rabinovitch PS, Wang D, Mattis AN, Ferrell LD, Choi WT| | PubMed
    10. DNA flow cytometric analysis of paraffin-embedded tissue for the diagnosis of malignancy in bile duct biopsies.
      Lee H, Rabinovitch PS, Mattis AN, Kakar S, Choi WT| | PubMed